Bonesupport Holding AB (BONEX)
Stockholm Exchange · Sweden · prices in SEK · close of 22 Oct 2026
Key indicators
| Last close | SEK 319.80 |
|---|---|
| 52-week range | 165.00 – 322.20 |
| Return, 1 month / 3 months | +49.3% / +53.3% |
| Return, 1 year / 3 years | +25.1% / +179.8% |
| Trend | Uptrend |
| RSI (14) | 85 |
| Volatility (1 year) | 53.0% |
| Worst drawdown (1 year) | -35.4% |
| Average daily value traded | 76.74M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bonesupport Holding AB is a Swedish medical device company based in Lund that develops injectable synthetic bone graft substitutes for orthopaedic use. Its main product family, CERAMENT, is a ceramic bone void filler that surgeons inject into bone defects, where it sets and is gradually replaced by new bone. The products are used in trauma and orthopaedic surgery, including procedures on the extremities and in infection-related bone treatment, and are sold to hospitals and specialist surgeons in several countries.
On this site Bonesupport Holding AB appears as a stock on the Stockholm Exchange (Sweden), code BONEX, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bonesupport Holding AB (BONEX) trades on the Stockholm Exchange in Sweden. It last closed at SEK 319.80 on 22 October 2026.
Its price-based Market X-Ray is 76 out of 100 (a strong price profile), ranking 100 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 25.1% and over the last three months it rose 53.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 47.7% | ||
| From 52-week high | 0.0% | ||
| Momentum | 75 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 53.3% | ||
| 6-month return | 25.9% | ||
| 12-month return, skipping the last month | -16.2% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 53.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.4% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 76.74M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +24.8% |
|---|---|
| 1 month | +49.3% |
| 3 months | +53.3% |
| 6 months | +25.9% |
| 1 year | +25.1% |
| 3 years | +179.8% |
| 5 years | +739.4% |
Signals
| 50-day / 200-day average | 230.02 / 216.54 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 13.44 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.